On The Threshold Of The Tumor Microenvironment
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.